ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0384

Serum Neutrophil Count Predicts Progression of Interstitial Lung Disease and Mortality in Patients with Systemic Sclerosis Related Interstitial Lung Disease

Nancy Wareing1, Ning Li2, Elizabeth Volkmann3, Marka Lyons4, Michael Roth2, Donald Tashkin2 and Shervin Assassi1, 1University of Texas Houston McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX, 2University of California, Los Angeles, Los Angeles, 3University of California, Los Angeles, Los Angeles, CA, 4University of Texas Houston, McGovern Medical School, Division of Rheumatology and Clinical Immunogenetics, Houston, TX

Meeting: ACR Convergence 2020

Keywords: clinical trial, neutrophils, prognostic factors, Scleroderma, Scleroderma, Systemic

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Friday, November 6, 2020

Title: Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Systemic sclerosis (SSc) patients have a prominent neutrophil gene expression signature.  However, investigations into the pathophysiologic role of neutrophils in SSc are lacking. This is predominantly due to their limited survivability in vitro and the significantly lower proportion of neutrophils in rodent serum compared to humans. These limitations highlight the need to directly study the role of neutrophils in SSc using human specimens. In this study, we examined the prognostic significance of neutrophil count in the Scleroderma Lung Study (SLS) II.

Methods: Neutrophil counts were prospectively obtained at the baseline visit of SLS II.  All subjects had clinically significant SSc related interstitial lung disease (ILD) and had a disease duration less than 7 years. Baseline neutrophil count was log-transformed with a base of 2 in all analyses. A joint model combining mixed effects and survival models was used to examine the relationship between baseline blood neutrophil count and serially obtained % predicted forced vital capacity (FVC%) as well as modified Rodnan skin scores (mRSS) from 3-12 month visits after adjustment for baseline disease severity and treatment arm. Cox proportional hazards models were created to evaluate the association between neutrophil count and long-term mortality.

Results: Of the 142 patients enrolled in SLS II, 134 (94.3%) had an available baseline neutrophil count. The majority of patients had diffuse cutaneous disease (59%) and mean disease duration was 2.6 years (±1.7). Higher neutrophil count predicted worsening of SSc-ILD based on the course of the FVC% from 3-12 months (p=0.030 – Table 1). Neutrophil count did not predict changes in mRSS. Baseline neutrophil count predicted an increased risk of mortality after adjustment for age (HR=2.02, 95% CI [1.02, 4.01], p=0.045-Table 2). The median follow-up time was 3.4 years with IQR (2.9, 4.6) for the mortality analysis. Both findings were independent of treatment arm.

Conclusion: Higher neutrophil count predicted worse ILD course and higher long-term mortality in patients with SSc-ILD. Our findings were independent of treatment with cyclophosphamide or mycophenolate. Neutrophils, largely under-investigated in SSc, might play a role in pathogenesis of SSc and warrant further mechanistic studies. Furthermore, baseline neutrophil counts may serve as a useful prognostic marker of disease progression.


Disclosure: N. Wareing, None; N. Li, None; E. Volkmann, Boehringer Ingelheim, 2, 5, Forbius, 2, 5, Corbus, 2; M. Lyons, None; M. Roth, Genentech/Roche, 1; D. Tashkin, None; S. Assassi, Momenta, 1, corbus, 1, Integrity Continuing Education, 1, Boehringer Ingelheim, 1, 2, 3.

To cite this abstract in AMA style:

Wareing N, Li N, Volkmann E, Lyons M, Roth M, Tashkin D, Assassi S. Serum Neutrophil Count Predicts Progression of Interstitial Lung Disease and Mortality in Patients with Systemic Sclerosis Related Interstitial Lung Disease [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/serum-neutrophil-count-predicts-progression-of-interstitial-lung-disease-and-mortality-in-patients-with-systemic-sclerosis-related-interstitial-lung-disease/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/serum-neutrophil-count-predicts-progression-of-interstitial-lung-disease-and-mortality-in-patients-with-systemic-sclerosis-related-interstitial-lung-disease/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology